bxq-350
Recombinant proteinexperimental
Clinical trial activity
6 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2016 (NCT02859857)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- bxq-350
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05322590 | Phase 1/Phase 2 (Phase 2) | Nov 30, 2022 | Bexion Pharmaceuticals, LLC., CTI Clinical Trial and Consulting Services, ICON |
| NCT05291286 | Early Phase 1 (Phase 1) | Oct 17, 2022 | Bexion Pharmaceuticals, LLC., CTI Clinical Trial and Consulting Services |
| NCT04771897 | Phase 1 | May 24, 2021 | Bexion Pharmaceuticals, LLC., CTI Clinical Trial and Consulting Services |
| NCT04404569 | Phase 1 | May 31, 2020 | Bexion Pharmaceuticals, LLC., CTI Clinical Trial and Consulting Services |
| NCT03967093 | Phase 1 | Apr 15, 2019 | Bexion Pharmaceuticals, LLC., CTI Clinical Trial and Consulting Services |
| NCT02859857 | Phase 1 | Sep 1, 2016 | Bexion Pharmaceuticals, LLC., CTI Clinical Trial and Consulting Services |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bexion Pharmaceuticals, LLC. | For profit | 6 | 6 | 2 | 2016 |
| CTI Clinical Trial and Consulting Services | For profit | 6 | 0 | 2 | 2016 |
| ICON | For profit | 1 | 0 | 1 | 2022 |
3 organizations
Page 1 / 1